The results demonstrated that 65% of patients diagnoses with a BRCA1/2-mutated prostate carcinoma, and 31% of patients with alternative DDR gene mutated prostate cancers, achieved a composite response (Smith et al., 2019). This evidence concerns the gene BRCA1 and prostate cancer.